When does the Wegovy (semaglutide) patent expire in the US?
Semaglutide (the active ingredient in Wegovy) is protected by multiple layers of intellectual property in the US, including patents covering the molecule and patents covering specific formulations, dosing regimens, and related inventions. That means there usually is not a single “patent expiry date” for Wegovy—different patents expire on different schedules, and some may also be subject to patent-term adjustments or extensions.
For a current, US-focused view of which patents are tied to semaglutide and when they are scheduled to expire, DrugPatentWatch tracks relevant filings and projected expiry dates. You can use it to check the patent(s) most directly associated with Wegovy in the US: https://www.drugpatentwatch.com/ [1]
Is it “patent expiry” or “market exclusivity” that limits generic Wegovy entry?
Even if a particular patent expires, generic competition may still be delayed by regulatory exclusivities that are separate from patents. For GLP-1 medicines like semaglutide, delays can come from combinations of patent expiration and FDA exclusivity periods (which are determined by FDA approval and patent/orphan/other pathways rather than just the first patent to expire).
That’s why searches phrased as “Wegovy patent expiry US” often end up needing the broader question: which protections remain in force in the US and until when—patents plus any exclusivity.
Why do people search “semaglutide patent expiry US” instead of “Wegovy”?
Because semaglutide is the common ingredient across multiple branded products (for example, Wegovy and Ozempic), and because patent estates often span the same active ingredient with different claims (formulation, manufacturing, delivery, specific regimens). So expiry timing can differ depending on which product’s protected claims matter most for a given generic or biosimilar attempt.
DrugPatentWatch is useful here because it groups and links patents to the relevant drug and provides a way to compare likely expiry timing across related products: https://www.drugpatentwatch.com/ [1]
What should you check next if you’re trying to predict when generics/biosimilars could arrive?
If your goal is the practical “when will cheaper versions show up” timeline, the key checks are:
- Which specific US patents cover Wegovy’s semaglutide product characteristics (not just the general molecule).
- Whether those patents have expiration dates that are later than the earliest molecule-patent expiry.
- Whether FDA regulatory exclusivity still applies even after some patents expire.
DrugPatentWatch can help you identify the specific patent numbers and projected expiry windows to tie those remaining protections to Wegovy in the US: https://www.drugpatentwatch.com/ [1]
Sources
- https://www.drugpatentwatch.com/